Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Valeant Pharmaceuticals Intl Inc    VRX   CA91911K1021

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Valeant Pharmaceuticals Intl : Health Care Higher As Paulson Joins Valeant Board - Health Care Roundup

share with twitter share with LinkedIn share with facebook
share via e-mail
0
06/19/2017 | 10:31pm CEST

Shares of health-care companies rose as one big investor endorsed one of the hardest hit companies during the recent retreat from the sector. Hedge-fund billionaire John Paulson joined the board of Valeant Pharmaceuticals International, a sign that the investor remains bullish on the drugmaker's prospects despite the rout in Valeant's shares over the last year. The specialty drugmaker came under pressure after allegations of accounting improprieties and lost the support of some big institutional holders, such as William Ackman's Pershing Square. Medical-test maker PerkinElmer said it would buy a German medical-diagnostics company Euroimmun Medical Laboratory Diagnostics for $1.3 billion, expanding its reach into autoimmune and allergy testing.

-Rob Curran, rob.curran@dowjones.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on VALEANT PHARMACEUTICALS IN
10/17 VALEANT PHARMACEUTICALS INTERNATIONA : Entry into a Material Definitive Agreemen..
10/17 VALEANT PHARMACEUTICALS INTL : Thinking about buying stock in Delta Airlines, Th..
10/17 VALEANT PHARMACEUTICALS INTL : And One Of Its Subsidiaries Announce Early Tender..
10/17 VALEANT PHARMACEUTICALS INTL : And One Of Its Subsidiaries Announce Early Tender..
10/16 VALEANT PHARMACEUTICALS INTL : International - Ortho Dermatologics Announces Two..
10/13 VALEANT PHARMACEUTICALS INTERNATIONA : Ortho Dermatologics Announces Two-Year Fi..
10/12 VRX INVESTOR ALERT : Kyros Law is Investigating Legal Claims on Behalf of Valean..
10/12 VALEANT PHARMACEUTICALS INTL : Announces Launch Of Private Offering Of Senior Se..
10/12 VALEANT PHARMACEUTICALS INTL : Bausch + Lomb Introduces Biotrue® ONEday for Asti..
10/12 VALEANT PHARMACEUTICALS INTL : And One Of Its Subsidiaries Commence Cash Tender ..
More news
Financials ($)
Sales 2017 8 687 M
EBIT 2017 3 267 M
Net income 2017 -498 M
Debt 2017 25 892 M
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales 2017 3,47x
EV / Sales 2018 3,31x
Capitalization 4 218 M
Chart VALEANT PHARMACEUTICALS IN
Duration : Period :
Valeant Pharmaceuticals In Technical Analysis Chart | VRX | CA91911K1021 | 4-Traders
Technical analysis trends VALEANT PHARMACEUTICALS IN
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
 
Mean consensus HOLD
Number of Analysts 18
Average target price 15,9 $
Spread / Average Target 31%
EPS Revisions
Managers
NameTitle
Joseph C. Papa Chairman & Chief Executive Officer
Paul S. Herendeen Chief Financial Officer & Executive VP-Finance
Tage Ramakrishna Chief Medical Officer, President-R&D
Robert N. Power Independent Director
David Robert Hale Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
VALEANT PHARMACEUTICALS INTL INC-14.05%4 218
JOHNSON & JOHNSON23.60%382 202
NOVARTIS13.50%226 404
PFIZER11.58%216 886
ROCHE HOLDING LTD.5.55%207 116
MERCK AND COMPANY7.88%174 223